ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders. The company has utilized this discovery to develop an HLA-based technology platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.

To treat cancer, ImmunOs is employing specific HLA molecules as the backbone of novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells. In contrast to other immuno-oncology therapies, the product candidates developed by ImmunOs’ platform address multiple targets of the innate immune system – specific leukocyte immunoglobulin-like receptors (LILRBs, which are also known as ILTs, i.e., immunoglobulin-like transcripts) and killer cell immunoglobulin-like receptors (KIRs) – via a single molecule. Therefore, ImmunOs´ product candidates target a broader range of immune cells than other competing approaches

To treat autoimmune diseases and reduce pro-inflammatory immune responses, ImmunOs is developing antibodies blocking the activation of specific HLA protein molecules associated with a broad set of autoimmune diseases, including ankylosing spondylitis, lupus, psoriasis, and IBD.

Background on Cancer Immunotherapy

Background on ImmunOs’ HLA-Based Technology Platform